Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of JSKN033 with platinum chemotherapy with or without bevacizumab in advanced cervical cancer
CTR20260927Phase 2Active
- Sponsor
- Kanion Pharmaceutical
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JSKN033 in Cervical Cancer (CC), sponsored by Kanion Pharmaceutical. Started May 2026; status: active.
02
Drugs
JSKN033
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20260927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260927.